Open AccessLong-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea
Author(s) -
Terri E. Weaver,
JeanLouis Pépin,
Richard J. Schwab,
Colin M. Shapiro,
Jan Hedner,
Mansoor Ahmed,
Nancy FoldvarySchaefer,
Patrick J. Strollo,
Geert Mayer,
Kathleen Sarmiento,
Michelle Baladi,
Morgan Bron,
Patricia Chandler,
Lawrence Lee,
Atul Malhotra
Publication year - 2021
Publication title -
journal of clinical sleep medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 92
eISSN - 1550-9397
pISSN - 1550-9389
DOI - 10.5664/jcsm.9384
Subject(s) - narcolepsy , medicine , obstructive sleep apnea , excessive daytime sleepiness , quality of life (healthcare) , epworth sleepiness scale , nausea , anxiety , somnolence , adverse effect , population , physical therapy , sleep disorder , insomnia , sleep apnea , modafinil , psychiatry , apnea , polysomnography , environmental health , nursing
Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the United States and European Union for excessive daytime sleepiness in adults with narcolepsy (75-150 mg/day) or obstructive sleep apnea (OSA; 37.5-150 mg/day). In 12-week studies, solriamfetol was associated with improvements in quality of life in participants with narcolepsy or OSA. These analyses evaluated the long-term effects of solriamfetol on quality of life.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom